VYGR biotech catalysts & pipeline

VOYAGER THERAPEUTICS INC · Data as of 2026-09-08

Upcoming catalysts

tau-targeting agents — Topline data

2026

● 2026: Potentially informative data read-outs expected for tau-targeting agents from multiple third parties

Source filing

VY1706 — IND submission

2026

2026: U.S. IND/Canadian CTA submissions + clinical trial initiation anticipated for VY1706 in AD

Source filing

VY7523 — Topline data

Q4 2026

• VY7523 (anti-tau antibody): Voyager expects tau positron emission tomography (PET) imaging efficacy data in Q4 2026 from the ongoing multiple ascending dose (MAD) clinical trial in participants with Alzheimer's disease (AD).

Source filing

VY1706 — Initial data

early 2027

including our plans to generate initial data from the Phase 1 multiple ascending dose clinical trial of VY7523 in early Alzheimer's disease patients in the fourth quarter of 2026 and to initiate and begin dosing patients in a clinical trial of VY1706 in the fourth quarter of 2026 and generate initial acute safety data and initial cerebrospinal fluid tau biomarker-based data in early 2027 and the second half of 2027, respectively;

Source filing

VY1706 — Initial data

H2 2027

including our plans to generate initial data from the Phase 1 multiple ascending dose clinical trial of VY7523 in early Alzheimer's disease patients in the fourth quarter of 2026 and to initiate and begin dosing patients in a clinical trial of VY1706 in the fourth quarter of 2026 and generate initial acute safety data and initial cerebrospinal fluid tau biomarker-based data in early 2027 and the second half of 2027, respectively;

Source filing

Explore the free biotech catalyst calendar